Xenon Pharma Prices Upsized $650M Offering at $57.00 Per Share
XENE has more than doubled off its 52-week low of $26.74 on elevated volume (3.3× avg).
Summary
Xenon Pharmaceuticals has priced its upsized public offering at $650.0 million, selling common shares at $57.00 each. This offering was increased from the previously announced $500.0 million on March 9th, which itself followed highly positive topline results from its Phase 3 X-TOLE2 study. While the offering provides substantial funding for the company's pipeline and operations, it is materially dilutive to existing shareholders, representing approximately 13% of the company's market capitalization, and is priced at a discount to the current market price. Traders will be watching the immediate market reaction to the dilution versus the strengthened balance sheet, especially given the recent positive clinical catalyst.
At the time of this announcement, XENE was trading at $60.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $26.74 to $63.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.